Compare MTZ & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTZ | BIO |
|---|---|---|
| Founded | 1929 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 7.1B |
| IPO Year | 2005 | N/A |
| Metric | MTZ | BIO |
|---|---|---|
| Price | $323.44 | $271.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $285.78 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 951.1K | 238.3K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.12 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $14,299,171,000.00 | N/A |
| Revenue This Year | $20.38 | $2.74 |
| Revenue Next Year | $10.02 | $3.05 |
| P/E Ratio | $59.28 | ★ $9.72 |
| Revenue Growth | ★ 16.22 | N/A |
| 52 Week Low | $99.70 | $211.43 |
| 52 Week High | $316.19 | $343.12 |
| Indicator | MTZ | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 48.13 |
| Support Level | $164.00 | $266.71 |
| Resistance Level | N/A | $289.61 |
| Average True Range (ATR) | 13.02 | 7.91 |
| MACD | 0.17 | 1.02 |
| Stochastic Oscillator | 96.28 | 42.97 |
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.